NCT06812260View on ClinicalTrials.gov

A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 24, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions

SCLC, Extensive Stage

Interventions

DRUG

HLX10+chemo

Treatment arm

Trial Locations (1)

Unknown

RECRUITING

Kansai Medical University Hospital Department of Respiratory Oncology, Hirakata

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY

NCT06812260 - A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC | Biotech Hunter | Biotech Hunter